TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05838599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 5% cream applied topically 5 days/week for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
Study: NCT06438003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Services
Description: Community members will complete data collection at the extension office or community partner location. Extension cooking classes and helping to make raised bed gardens along with other area happenings will be offered to participants throughout the year with check-ins and reminders. Data will be collected from study participants (regardless of the intervention decided) , at two time points, to include survey, dietary recall, and carotenoid scanner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Community members will receive extension services as usual with Data collection on participants at two time points to assess changes in rates of food insecurity, dietary quality, and overall health conditions.
Study: NCT04131803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifico combined with chemotherapy plus targeted therapy
Description: Bifico combined with chemotherapy plus targeted therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus targeted therapy
Description: chemotherapy plus targeted therapy
Study: NCT05652842

Intervention type: BEHAVIORAL
Intervention: Work-type
Description: Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.

Intervention type: BEHAVIORAL
Intervention: Work-type
Description: Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.

Intervention type: BEHAVIORAL
Intervention: Work-type
Description: Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
Study: NCT05362084

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lumbar medial branch block
Description: lumbar medial branch block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar medial branch block
Description: lumbar medial branch block
Study: NCT04999969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0171
Description: AZD0171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (Standard-of-Care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Chemotherapy (Standard-of-Care)
Study: NCT05927415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod
Study: NCT05576220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDION iTempShield
Description: Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
Study: NCT04849013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 100mg
Description: Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 200mg
Description: Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 400mg
Description: Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 800mg
Description: Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 800mg + Ketanserin 40mg
Description: Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose
Study: NCT05856435

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Chicago Parent Program for Foster Care
Description: The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
Study: NCT04810156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-Medrol
Description: 2 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
Study: NCT05920226

Intervention type: DEVICE
Intervention: pacemakers implantation and assessment of cardiac function and cardiac fibrosis
Description: 150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia).

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of cardiac function and cardiac fibrosis
Description: The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
Study: NCT05540899

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Postoperative Radiotherapy
Description: Hypofractionated Postoperative Radiation Therapy
Study: NCT04651712

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC-PCR
Description: The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
Study: NCT05527080

Intervention type: OTHER
Intervention: physiotherapy
Description: Some infants will receive physiotherapy as a part of their clinically indicated care.

Intervention type: DEVICE
Intervention: brace
Description: Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
Study: NCT04490356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legacy Intervention
Description: The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
Study: NCT06342141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 milgrams (Mg)
Description: Load dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 Mg
Description: Maintenance dose
Study: NCT05054881

Intervention type: OTHER
Group type: OTHER
Intervention: sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator
Description: Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.

Intervention type: OTHER
Group type: OTHER
Intervention: sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator
Description: Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study: NCT06059859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented reality robot-assited radical prostatectomy
Description: Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed reality intraoperative frozen section analysis
Description: Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assited radical prostatectomy
Description: Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
Study: NCT04607096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
Study: NCT05957081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMC-309 monotherapy
Description: PMC-309 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMC-309 Dose Escalation in Combination with Pembrolizumab
Description: Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMC-309 Dose Expansion
Description: Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  - PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab
Study: NCT04716322

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Physical Activity
Description: A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
Study: NCT05655585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Bent Leg Raise
Description: Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Bent Leg Raise
Description: Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
Study: NCT06588153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolia®
Description: Subcutaneous (SC) injection in pre-filled syringe.
Study: NCT06236191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial pulsed current stimulation
Description: A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin
Study: NCT04817852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBCT data of c-shaped canal in mandibular second molar.
Description: Detection of variation in root canal morphology in mandibular second molar by using CBCT.
Study: NCT05582954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EsteemUp
Description: EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EsteemUp
Description: EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EsteemUp-G
Description: The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program